Your browser doesn't support javascript.
loading
Rapid turnaround multiplex sequencing of SARS-CoV-2: comparing tiling amplicon protocol performance
Bede Constantinides; Hermione Webster; Jessica Gentry; Jasmine Bastable; Laura Dunn; Sarah Oakley; Jeremy Swann; Nicholas D Sanderson; Philip W Fowler; Geoffrey Ma; Gillian Rodger; Lucinda Barrett; Katie JM Jeffery; Timothy EA JM Peto; Nicole Stoesser; Teresa L Street; Derrick W Crook.
Afiliación
  • Bede Constantinides; NDM Experimental Medicine, University of Oxford
  • Hermione Webster; NDM Experimental Medicine, University of Oxford
  • Jessica Gentry; Oxford University Hospitals NHS Foundation Trust
  • Jasmine Bastable; Oxford University Hospitals NHS Foundation Trust
  • Laura Dunn; Oxford University Hospitals NHS Foundation Trust
  • Sarah Oakley; Oxford University Hospitals NHS Foundation Trust
  • Jeremy Swann; NDM Experimental Medicine, University of Oxford
  • Nicholas D Sanderson; NDM Experimental Medicine, University of Oxford
  • Philip W Fowler; NDM Experimental Medicine, University of Oxford
  • Geoffrey Ma; NDM Experimental Medicine, University of Oxford
  • Gillian Rodger; NDM Experimental Medicine, University of Oxford
  • Lucinda Barrett; Oxford University Hospitals NHS Foundation Trust
  • Katie JM Jeffery; Oxford University Hospitals NHS Foundation Trust
  • Timothy EA JM Peto; NDM Experimental Medicine, University of Oxford
  • Nicole Stoesser; NDM Experimental Medicine, University of Oxford
  • Teresa L Street; NDM Experimental Medicine, University of Oxford
  • Derrick W Crook; NIHR Oxford Biomedical Research Centre
Preprint en En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21268461
ABSTRACT
Genome sequencing is pivotal to SARS-CoV-2 surveillance, elucidating the emergence and global dissemination of acquired genetic mutations. Amplicon sequencing has proven very effective for sequencing SARS-CoV-2, but prevalent mutations disrupting primer binding sites have necessitated the revision of sequencing protocols in order to maintain performance for emerging virus lineages. We compared the performance of Oxford Nanopore Technologies (ONT) Midnight and ARTIC tiling amplicon protocols using 196 Delta lineage SARS-CoV-2 clinical specimens, and 71 mostly Omicron lineage samples with S gene target failure (SGTF), reflecting circulating lineages in the United Kingdom during December 2021. 96-plexed nanopore sequencing was used. For Delta lineage samples, ARTIC v4 recovered the greatest proportion of [≥]90% complete genomes (81.1%; 159/193), followed by Midnight (71.5%; 138/193) and ARTIC v3 (34.1%; 14/41). Midnight protocol however yielded higher average genome recovery (mean 98.8%) than ARTIC v4 (98.1%) and ARTIC v3 (75.4%), resulting in less ambiguous final consensus assemblies overall. Explaining these observations were ARTIC v4s superior genome recovery in low viral titre/high cycle threshold (Ct) samples and inferior performance in high titre/low Ct samples, where Midnight excelled. We evaluated Omicron sequencing performance using a revised Midnight primer mix alongside prototype ARTIC v4.1 primers, head-to-head with the existing commercially available Midnight and ARTIC v4 protocols. The revised protocols both improved considerably the recovery of Omicron genomes and exhibited similar overall performance to one another. Revised Midnight protocol recovered [≥]90% complete genomes for 85.9% (61/71) of Omicron samples vs. 88.7% (63/71) for ARTIC v4.1. Approximate cost per sample for Midnight ({pound}12) is lower than ARTIC ({pound}16) while hands-on time is considerably lower for Midnight ([~]7 hours) than ARTIC protocols ([~]9.5 hours).
Licencia
cc_by_nd
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2022 Tipo del documento: Preprint
Texto completo: 1 Colección: 09-preprints Base de datos: PREPRINT-MEDRXIV Tipo de estudio: Experimental_studies / Observational_studies / Prognostic_studies Idioma: En Año: 2022 Tipo del documento: Preprint